Sluggish Anti-Infective Season
Q4 domestic decline was partly due to a weak anti-infective season; if FY25 monsoon is poor, acute portfolio growth may underperform.
medium · analyst_questionAlkem Laboratories Limited — Q4 FY24
Alkem Laboratories reported Q4 FY24 PAT of INR 294 crore, impacted by a deferred tax derecognition of INR 120 crore.
bullish
medium
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Raw Material Cost Inflation
While API prices are stable, any black swan event could increase costs; Pen G price decline has not materialized as expected.
medium · management_commentaryUS Supply Chain Penalties
Q4 had INR 30 crore in service-level penalties due to supply issues; if not resolved, could impact US margins.
medium · management_commentaryBaddi Site FDA Observations
Baddi site received 10 observations from US FDA; though management downplayed, any escalation could delay approvals.
low · analyst_question